Abstract: A method includes a gateway node that obtains a data transmission parameter between a first-level node and each node in a first node set, where the first-level node is located on a first-level power distribution device in a power distribution grid, and the first node set includes a node located on a power distribution device at another level in the power distribution grid other than the first-level power distribution device; determines a second-level node directly coupled to the first-level node from the first node set based on the data transmission parameter between the first-level node and each node in the first node set; and generates a physical network topology of the power distribution grid.

Abstract: The present disclosure relates to a compound containing cycloalkyl or haloalkyl, and specifically discloses a compound represented by formula I?, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof in treating tumors.

Abstract: Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.

Abstract: Provided is the use of an anti-CD40 antibody, specifically, provided is a combined drug for treating cancer. The combined drug comprises an anti-CD40 antibody or an antigen-binding portion thereof and a tyrosine kinase inhibitor, and has a good anti-tumor activity and safety.

Abstract: The invention is in the field of antibody formulations, and particularly relates to a pharmaceutical composition of a humanized monoclonal anti-PD-L1 antibody, wherein the pharmaceutical composition comprises 1-150 mg/ml of the humanized monoclonal anti-PD-L1 antibody, a buffer at 3-50 mM, 2-150 mg/ml of an isotonic adjuster/stabilizer and 0.01-0.8 mg/ml of a surfactant, and has a pH of about 4.5-6.8. The formulations prevent antibody aggregates therein from increasing, while enabling better maintenance of the biological binding activity of the antibody for a long time.

Abstract: The present disclosure relates to a combined pharmaceutical composition of a CDK4/6 inhibitor and an aromatase inhibitor, and the use thereof in the treatment of breast cancer. Compared with separate administration of any agent in the composition, the combined pharmaceutical composition of the present disclosure yields a better therapeutic effect on slowing tumor growth or even eliminating tumors.

Abstract: The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.

Abstract: Provided is a pharmaceutical composition for treating small cell lung cancer, which comprises an anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and a chemotherapeutic drug. Further provided is the use of the pharmaceutical composition or a kit containing the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof and the chemotherapeutic drug in the preparation of a drug for treating small cell lung cancer. Further provided is a method for treating small cell lung cancer, comprising administering to a patient in need thereof a therapeutically effective amount of the anti-PD-L1 antibody, anlotinib or a pharmaceutically acceptable salt thereof, and the chemotherapeutic drug.

Abstract: The present invention relates to the use of a pyrrolopyrimidine compound and a pharmaceutical composition thereof for treating chronic graft versus host disease, and particularly relates to the use of a compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof for treating chronic graft versus host disease.

Abstract: An anti-CD47 antibody for combined treatment of a blood tumor. Provided are the use of the anti-CD47 antibody and a second therapeutic agent in the preparation of a drug for treating a blood tumor in a subject. Provided is a method for treating a blood tumor in a subject, comprising administering a therapeutically effective amount of the anti-CD47 antibody and the second therapeutic agent to a subject. Also provided are a pharmaceutical combination comprising the anti-CD47 antibody and the second therapeutic agent, and a kit.

Abstract: The present disclosure relates to a combined pharmaceutical composition containing a CDK4/6 inhibitor and a use thereof, and specifically relates to a combined pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and fulvestrant. The present disclosure further relates to a use of the combined pharmaceutical composition in treating breast cancer. The combined pharmaceutical composition of the present disclosure produces better therapeutic effects in reducing tumor growth or even eliminating tumors.

Abstract: A crystal form and salt form of a bromine domain protein inhibitor represented by formula (I), a preparation method therefor, and a use of the crystal form and salt form in the preparation of a drug for treating diseases mediated by BET protein.

Abstract: A salt form of a tetra-substituted olefin compound, a crystal of the compound and the salt, and a preparation method relating to a crystal of a compound represented by formula (I), a salt thereof, a crystal of the salt thereof, and a preparation method therefor.

Abstract: A data transmission time obtaining method, apparatus, and system are provided. The method includes: A first device sends a first packet to a second device, and obtains a first send timestamp of the first packet; the first device receives a second packet that is sent by the second device and that corresponds to the first packet, and obtains a first receive timestamp of the second packet; the first device calculates, based on timing frequency of the second device, a second receive timestamp at which the second device receives the first packet and a second send timestamp at which the second device sends the second packet; and the first device calculates a data transmission time between the first device and the second device based on the first send timestamp, the first receive timestamp, the second send timestamp, and the second receive timestamp.

Abstract: The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

Abstract: Provided is an antibody drug conjugate, specifically comprising a therapeutic antibody moiety, an intermediate linker moiety and a cytotoxic drug moiety which are linked. The therapeutic antibody moiety is an antibody against an HER2 target. The cytotoxic drug moiety is a camptothecin topoisomerase I inhibitor. The cytotoxic drug moiety or the linker-cytotoxic drug moiety is modified by means of deuterium substitution. The antibody drug conjugate can be used for the prevention or treatment of cancers.

Abstract: A preparation method for a CDK4/6 inhibitor for a compound of formula (I): 5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)-N-(5-(piperazin-1-yl)pyrazol-2-yl)pyrimidine-2-amine. The preparation method has cheap and readily available starting materials and reagents, greatly simplified total reaction steps, shortened reaction time, improved total yield and a high purity of the key intermediate and final product, being suitable for industrial production.

Abstract: The present invention belongs to the field of biomedicines, relates to a drug for treating tumors, and provides use of an anti-PD-L1 antibody or a pharmaceutical composition thereof in preparation of a drug for treating endometrial cancer. Also provided is use of the anti-PD-L1 antibody or the pharmaceutical composition thereof in preparation of a drug for treating a MSI-H and/or dMMR tumor. In addition, also provided is use of a pharmaceutical combination of the anti-PD-L1 antibody and Anlotinib or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in preparation of a drug for treating endometrial cancer.

Abstract: Provided is an ST2 antigen binding protein, such as a mouse, human, chimeric or humanized antibody or antigen binding fragment thereof that specifically binds to ST2. Also provided are nucleic acid molecules encoding the above-mentioned antibodies and antigen binding fragments thereof, and an expression vector and host cell for expressing the antibodies or antigen binding fragments thereof. Further provided are methods for preparing and using the antibodies and antigen binding fragments thereof. The methods comprise treating and preventing IL33/ST2-mediated related diseases or conditions.

Abstract: An immunoglobulin single variable domain and antigen binding molecule binding BCMA, specifically comprising an immunoglobulin single variable domain and antigen binding molecule, a nucleic acid for encoding the binding molecule, a vector containing the nucleic acid, a cell containing the vector, and a pharmaceutical composition containing the above.